Market Access Impact: Haemophilia B (US) 2018

Maximum Purchase:
1 unit
Publication Date:
June 2018
Adding to cart… The item has been added

Market barriers affect 15 percent of haemophilia B prescriptions in the US. Is your brand losing out?

Despite market barriers only affecting 15 percent of all haemophilia B prescriptions in the US, certain brands are losing out on market share. Is it yours? Find out what’s driving share gains, and what your brand can do to level the playing field in Market Access Impact: Haemophilia B (US) [2018].

Based on a survey of 100 haematologists, the report covers 7 major therapies from Shire, Bioverativ, Sanofi, CSL Behring, Novo Nordisk and Pfizer. Handy graphs and charts reveal which  of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Interested in the European market? Click here to see the EU5 Edition.

Request sample pages

Top Takeaways

  • Barriers affect 15 percent of all prescriptions. Small, perhaps, but brands are still losing out on market share opportunities because of them. Is it cost, formulary issues or some other barrier combinations that cause the most amount of pain?
  • Two brands see the biggest share increases. But are they so far ahead that other brands can’t catch up? And is your brand leading, or in the chasing pack?
  • One brand sees a significant loss. Despite being prescribed by over 60 percent of physicians, one brand loses nearly 1 percent of its market share because of barriers. Why? And can this be prevented?
  • Eliminating barriers would close gaps across the table. And certain products would move up several places, suggesting an improved market access strategy could drive significant market share gains.
  • Perception could be a problem for some brands. Across all 7 brands, awareness and a willingness to use is high. But for one brand, over 10 percent of physicians wouldn’t even consider using it? Is it your brand?

Insight into 7 Major Haemophilia B Treatments

  • Alprolix (eftrenonacog alfa; Bioverativ/Sanofi)
  • BeneFIX (nonacog alfa; Pfizer)
  • Feiba (Anti-Inhibitor Coagulant Complex; Shire)
  • Idelvion (albutrepenonacog alfa; CSL Behring)
  • MonoNine (Coagulation Factor IX (human); CSL Behring)
  • Rixubis (nonacog gamma; Shire)
  • Rebinyn (nonacog beta pegol; Novo Nordisk)

Exploring Market Access Barriers

Market Access Impact: Haemophilia B (US) [2018] explores key issues affecting haemophilia B drug manufacturers. You’ll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don’t, but would consider it?
  • Why don’t doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 100 US-based haematologists, chosen from the largest community of validated physicians in the world. All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with haemophilia B in total in the last month

We conducted the survey between June 4-15, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at